Raymond James Financial
ACAD icon

Raymond James Financial’s Acadia Pharmaceuticals ACAD Stock Holding History

Raymond James Financial’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$711K Buy
31,923
+11,274
+55% +$269K ﹤0.01% 4106
2025
Q4 		$552K Sell
20,649
-4,549
-18% -$109K ﹤0.01% 4202
2025
Q3 		$538K Sell
25,198
-4,481
-15% -$106K ﹤0.01% 4082
2025
Q2 		$640K Buy
29,679
+1,396
+5% +$25.9K ﹤0.01% 3851
2025
Q1 		$470K Sell
28,283
-7,878
-22% -$143K ﹤0.01% 3967
2024
Q4 		$664K Buy
+36,161
New +$584K ﹤0.01% 3724

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Raymond James Financial's ACAD Position: Q1 2026 in Review

Raymond James Financial increased its Acadia Pharmaceuticals (ACAD) stake by 55% in Q1 2026, buying an estimated $269K and bringing the position to 31,923 shares worth $711K. The position accounts for ﹤0.01% of the portfolio, ranked #4106.

Raymond James Financial first reported a position in ACAD in Q4 2024 and has held it in 6 quarters since. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Raymond James Financial held 31,923 shares of Acadia Pharmaceuticals worth $711K as of Q1 2026.
  • Raymond James Financial bought 11,274 Acadia Pharmaceuticals shares in Q1 2026, an estimated $269K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #4106 holding.
  • Raymond James Financial first reported a position in Acadia Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.